Summary

Treatment with levodopa-carbidopa intestinal gel leads to reduction in nonmotor symptoms in patients with advanced Parkinson’s disease, with significantly lower Non-Motor Symptoms Scale total scores and scores for the individual domains of sleep/fatigue, sexual function, and miscellaneous. Safety results are similar to those seen in prior studies with levodopa-carbidopa intestinal gel.